Ekso Bionics Reports Record Annual Revenue of $18.3 Million
SAN RAFAEL, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023.
- Sales and marketing expenses for the quarter ended December 31, 2023 were $2.0 million, compared to $1.9 million for the same period in 2022.
- Research and development expenses for the quarter ended December 31, 2023 were $1.3 million, compared to $0.9 million for the same period in 2022.
- General and administrative expenses for the quarter ended December 31, 2023 were $2.5 million, compared to $3.2 million for the same period in 2022.
- Revenue for the full year ended December 31, 2023 was $18.3 million, an increase of 42% compared to $12.9 million for the same period in 2022.